Brecon appoints new Head of Clinical Trials Services
Brecon Pharmaceuticals launches Hereford recruitment drive
Total Show Press Release
Brecon's labelling service enhanced
Brecon Pharmaceuticals opens new Analytical Lab
Optimising the Value of Outsource Partners
New SV2 boosts Brecons bottling capacities
Planning go-ahead for major new facility

Brecon appoints new Head of Clinical Trials Services

Leading pharmaceutical outsource services provider Brecon Pharmaceuticals has appointed Dr Susan Miles as Head of Clinical Trials Services.

Sue Miles is a graduate from Cambridge University with a PhD from the Faculty of Medicine at Edinburgh University. She was previously Chief Executive Officer of Quantum Research UK, which provides electrocardiography, respiratory and blood pressure monitoring support for the clinical trials industry.

Commenting on the new appointment, Brecon’s Chief Executive John Bath said, “Clinical Trials Services has become a major area of business growth for us. We already have a well-respected presence in this market and offer excellent quality, service and value for our customers. We are delighted that we have someone with Sue’s extensive market experience to head up the team.”

Sue Miles believes Brecon is well placed to capitalise on the many opportunities that will result from the introduction of the new EC Clinical Trials Directive. She said, “I am looking forward to supporting Brecon in the development of its Clinical Trials Services. The new EC Directive will make choosing a clinical trial service provider an even more crucial decision and I believe Brecon is well placed to meet customers’ demands.”

19 April 2021

Back to top

Brecon Pharmaceuticals launches Hereford recruitment drive

Brecon Pharmaceuticals Ltd, one of the UK’s leading service providers to the global pharmaceutical industry, is holding a recruitment event in Hereford on Wednesday 14 April to highlight the many new job opportunities that are being created by its major new expansion programme.

Over the next 12 months Brecon will be doubling the size of its existing operation in Hay-on-Wye with the development of a major new production and warehouse facility. Brecon currently employs over 230 people from throughout the region and the state-of-the-art development will create up to 100 new jobs, which will confirm Brecon’s position as a leading employer in the region.

The recruitment event is being held at The Green Dragon Hotel in Hereford on Wednesday 14 April from 8.30 am to 7.30 pm. Members of Brecon’s team will be on hand to answer any queries and to advise on the benefits that the company provides its employees. Brecon’s CEO John Bath will be attending the event and will be giving a series of short presentations throughout the day at 11am, 1pm, 4pm and 6 pm, to illustrate the company’s future development plans.

Brecon currently attracts its workforce from a wide area - from the Valleys in the South to Leominster in the North. It has developed a strong reputation as a leading employer in the region through the provision of excellent career opportunities, a modern and friendly working environment and good benefit packages for its employees.

Brecon’s Personnel Manager Pauline Tarrant believes that Hereford is a key area for the company’s recruitment drive. She said, “Brecon has expanded rapidly in recent
years and we have attracted employees from throughout the region. Hereford is only 20 miles from our facility in Hay-on-Wye and we will be offering transport links for those who join us. Our major new development will create up to 100 new jobs in a range of areas from production through to administration. We welcome visitors to our event on 14 April and look forward to telling them all about the many opportunities that Brecon can provide.”

5 April 2021

Back to top

Total Show Press Release -
Brecon Pharmaceuticals presents a trio of major new developments for 2004

Leading pharmaceutical outsource services provider, Brecon Pharmaceuticals Ltd will be presenting a trio of major new business developments at the Total Packaging and Processing Exhibition at NEC 29 March - 1 April 2004.

Brecon’s stand IG80 is situated in Hall 1 and visitors to the stand will be introduced to the details of the company’s major new development programme for 2004/5, which includes:

Major New Expansion
Brecon is doubling the size of its operation at the Wye Valley Business Park to cater for its continued growth. The construction of a new 45,000 sq ft business unit begins in late Spring 2004 and will create new state-of-the-art production and warehouse facilities to complement Brecon’s existing operation.

A major recruitment drive is under way to support the new development that will ultimately take Brecon’s workforce to over 330 personnel, making it one of the largest employers in the region.

A scale model of the new development will be available on Brecon’s stand to illustrate the plans in detail.

Launch of New Analytical Laboratory
Brecon launched a new purpose-built analytical laboratory at the start of 2004. The 95 sq m state-of-the-art facility provides a wide range of services to match the needs of multi-national clients, virtual organisations and global pharmaceutical companies. Brecon’s customers can now benefit from an extensive range of clinical trial services including simple identification testing and analytical method transfers through to complete finished product and ICH stability testing.

New Child-Resistant/Senior Friendly (CRSF) Blister Pack Capabilities
Following the MHRA announcement to make CRSF packaging a legal requirement on certain blister packs, Brecon Pharmaceuticals is delighted to announce that it is the first UK company to introduce BS 8404 approved CRSF blister pack capabilities in-line, using the latest Pill Protect ™ technology. Pill Protect ™ will be joining Brecon’s team on the stand to illustrate this latest CRSF pack solution.

Brecon Pharmaceuticals -
Serving the Pharmaceutical Industry with Confidence

March 2004

Back to top

Brecon's labelling service enhanced

Specialist pharmaceutical outsource packaging company Brecon Pharmaceuticals Ltd has upgraded its clinical trial labelling capabilities with the recent installation of the latest MAP80 PRISYM 2000 software to provide label design, printing and generation of randomisations.

The MAP80 software has been installed in Brecon’s dedicated labelling suite, which has two printing areas and a separate checking area for increased security.

The new system is one of the most powerful and flexible labelling and product identification software packages available and is fully compatible with Windows 2000 and NT. Its capabilities include differing levels of access, assigned through restricted password controls and the ability to create varying label designs, i.e. single label, 2-Part label and upwards. The system can also provide multi-language designs, which can achieve most true type fonts with international character support.

The system is able to generate randomisations for parallel, crossover, scrambled and alpha-numeric trials. Other features available are bar coding, including variable bar codes, any form of keyboard prompts, sequential numbering and graphic formats which can be exported for customer approval without compromising version control. The system also provides audit trails for traceability of tasks undertaken by all personnel.

Brecon’s Operations Director Andrew Billington believes the new system sets the industry standard and further expands the productivity of Brecon’s clinical trials operations. He said, “We commonly use databases for trials where the information on each pack or bottle may vary, with different patient or pack numbers. Some projects may require up to 5000 labels, all of which may have differing information, but must look identical for blinding purposes. This is particularly important when placebos or different strengths of active drugs are used, as the packs must be indistinguishable. The new system provides the precision label printing we require using a validatable procedure.”

5 March 2004

Back to top

Brecon Pharmaceuticals opens new Analytical Lab

Brecon Pharmaceuticals Ltd has begun 2004 with the launch of its new purpose-built analytical laboratory, which offers customers access to the highest quality clinical trials, commercially packed product or stand-alone analytical services.

The 95 sq m state-of-the-art facility provides a wide range of services to match the needs of multi-national clients, virtual organisations and global pharmaceutical companies. Brecon’s customers can benefit from an extensive range of clinical trial services including simple identification testing and analytical method transfers through to complete finished product and ICH stability testing.

The new lab aims to be compliant with current European Good Manufacturing Practice (GMP), ICH and FDA requirements, which will enable Brecon to provide stability testing and studies to full ICH standard. Method validation or the further development and updating of methods can also be offered, together with extra validation to GMP standards as required.

To maximise the versatility of the lab, additional facilities have been incorporated including a dark room for light sensitive products, a large fume cupboard and a containment room for cytotoxic drugs. The containment room has a dedicated, negative pressure HEPA filtered air-handling system for the preparation and analysis of less well characterised development drugs.

The lab equipment has been specified to the highest standards and features: flexible HPLCs for method development, semi micro analytical balance equipment, Coulometric Karl Fischer apparatus, dissolution baths, disintegration apparatus, hardness testers, a friabulator and colour meter together with equipment to carry out a wide range of pharmacopaeial analysis.

The air-conditioned facility can house up to eight analysts with the capacity to expand to 16 analysts when required. The analyst team can provide customers with an extensive report writing service covering protocol generation, certificates of analysis, method transfer, validation and ICH stability reports.

Manager of Quality Services, Dr Karl Fry QP heads up the new analytical team. He believes the new lab positions Brecon at the forefront of the industry. He said, “This is an exciting development for Brecon and one that I believe will prove popular with existing and future clients”.

Jan 2004

Back to top

22nd January 2004

Back to top

New SV2 boosts Brecons bottling capacities

Leading pharmaceutical outsource packaging company Brecon Pharmaceuticals Ltd, has increased its bottling capabilities with the introduction of a new Swiftpack SV2-12-EFS to complement its existing bottling lines.

The advanced new SV2, which handles a wide range of bottle and cap designs including both screw on and push on, has been integrated into Brecon’s automatic line to provide capper, checkweigher, labeller, cartonner and bandwrapper capabilities. Both the cartonner and labeller systems are fitted with Pharmacode e and other component verification systems.

The new SV2 also incorporates an electrostatic counting system rather than a traditional visual system. This new system significantly increases its product sensitivity and enables it to detect and reject any minute physical characteristics of non-conforming products, such as broken tablets

The new high-speed line, which handles up to 55 bottles per minute, has been installed in a purpose built cubicle in Brecon’s new production facility, which operates under class 8 (ISO 14644-1) clean room conditions.

Commenting on the new line, Brecon’s Operations Director Andrew Billington said, “The new high speed system has proved extremely efficient in our initial production runs. During the validation process we found that the advanced detection facility was even able to detect product that had been exposed to any moisture though being held in a bare hand or left exposed to the atmosphere. The new SV2 is valuable addition to our existing bottling line and has enhanced our speed and efficiency for customers on a wide range of bottle and cap designs.”

18 January 2004

Back to top

Planning go-ahead for major new facility

Brecon Pharmaceuticals Ltd has gained planning permission for a new factory and warehouse facilities at its Wye Valley Business Park site in Hay-on-Wye. The company currently employs 235 staff and this latest expansion would see as many as 115 further jobs created.

Brecon is already Hay-on-Wye’s largest employer and the company continues to expand in terms both of capacity and capabilities in line with the increasing demand in the market for its high quality services.

Permission was granted at a meeting of the Brecon Beacons National Park’s planning control committee, where member were told the expansion would be good for the town. Reported in the Brecon & Radnor Express, Park member, Ross Murray said: “The people of Hay must think that Christmas has come early. It is an extremely positive thing for a small Mid-Wales market town to have an employer of this quality”.

The newspaper says Brecon chairman, Leon Morelli, told the meeting that the company is a key figure in the town’s economy, “Our further investment is vital to the wealth of the our local economy. We offer secure, well paid jobs with career potential and profit share for all employees.”

The committee also heard that Brecon was committed to being a good neighbour. “We hold the ISO14001 environmental standard which requires us publicly to commit to improve over time as an integral part of our business plan. That commitment makes us good neighbours,” said Mr Morelli.

This latest development has been prompted by ongoing growth in demand for Brecon’s clinical trial supply and commercial packaging services and further supports the company’s declared mission of “Growth through Excellence”.

Chief Executive John Bath said: “Brecon has a fundamental commitment to quality in every area of our operations. We have built-up a reputation for delivering the highest possible standard of service at competitive prices, and this is now being reflected in the level of demand we are experiencing. These new facilities will enable us continue serving our customers to the levels they expect, while offering them even greater flexibility and capabilities.”

3rd October 2003

Back to top